Overview
- Cipla will distribute and promote Yurpeak nationwide, while Eli Lilly will manufacture and supply the tirzepatide product.
- Yurpeak is a once-weekly dual GIP/GLP-1 injection in KwikPen format with six strengths from 2.5 mg to 15 mg, available by prescription.
- List prices match Mounjaro, with media citing roughly Rs 14,000 to Rs 27,500 per month depending on dose.
- Pharmatrac data show Mounjaro remained India’s top-selling medicine brand, posting about Rs 100 crore in October sales and Rs 108 crore in November.
- Following sharp cuts to roughly Rs 2,700–4,100 per dose, Wegovy’s consumption rose about 70%, lifting its share to 14% as Mounjaro dipped to 86%, with demand strongest in Maharashtra and Delhi-NCR and lower in states such as Uttar Pradesh, Bihar, West Bengal and Madhya Pradesh.